| 查看: 394 | 回复: 0 | |||
[交流]
“Metabolite signaling causing fatty liver disease”
|
|
A postdoctoral fellow position available in “Metabolite signaling causing fatty liver disease” A postdoctoral position for 2 years is available in the laboratory of Philipp Kaldis at Lund University (https://portal.research.lu.se/en/persons/philipp-kaldis). We are using a combination of omics-approaches (RNAseq, ChIPseq, metabolomics, and lipidomics) and mouse genetics to study how metabolism is re-wired during liver disease and diabetes as a function of cell division (eLife 9:e63835, Developmental Cell 47:425-438; Hepatol Int. 14:463-474; PLOS Genetics 16:e1009084, for a summary of our current work see: https://researchoutreach.org/art ... ion-liver-beyond/). We are looking for a highly motivated postdoctoral fellow that can drive research projects, wants to further her/his career, and will be collaborating with multiple research groups internationally. We are located at the Lund University Diabetes Center (LUDC), Clinical Research Centre (CRC) in Malmö, Sweden (across the bridge from Copenhagen), which is an excellent environment to do research with many research and clinical groups close by. Requirements: PhD in Cell, Molecular Biology, Biochemistry, or Genetics (less than 3 years since graduation) Experience in metabolism, liver biology, or mouse genetics Enthusiastic, passionate, and hard working Proficient in laboratory techniques like qPCR, cloning, WB, and cell culture Able to communicate in English Interested applicants should send a CV, publication list, a brief description of research interests and experience, and three confidential letters of reference to: Prof. Philipp Kaldis philipp.kaldis@med.lu.se |
回复此楼» 猜你喜欢
HILIC磁珠研究蛋白组学怎么做？
已经有0人回复
-
His标签蛋白纯化怎么才能快？
已经有0人回复
-
化学工程及工业化学论文润色/翻译怎么收费?
已经有139人回复
-
WRN变构抑制剂HRO761：从D1/D2界面锁定到MSI合成致死的工具化合物深度解析
已经有0人回复
-
KRAS G12V(ON) 选择性抑制剂 RMC-5127：从三元复合物机制到科研应用
已经有0人回复
-
SHP2 变构抑制剂 Sitneprotafib：从作用机制到科研试剂选型要点
已经有0人回复
-
PRMT5·MTA 抑制剂 MRTX1719 的科研应用
已经有0人回复
-
SW033291 科研使用解析：分子特征、储存与实验获取要点
已经有0人回复
-
泛 RAS 抑制新思路：大环肽拟似物如何同时牵住突变型与野生型 RAS？
已经有0人回复
-
TYK2/JAK1 双靶点工具化合物 Brepocitinib：激酶选择性、研究进展与实验应用全解析
已经有0人回复
-
矢车菊素-3-O-葡萄糖苷质控实录：从一张HPLC图谱读懂纯度与稳定性
已经有0人回复